Acceleron Pharma Inc. (XLRN): Price and Financial Metrics


Acceleron Pharma Inc. (XLRN): $178.75

-0.93 (-0.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XLRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 474

in industry

XLRN POWR Grades


  • XLRN scores best on the Growth dimension, with a Growth rank ahead of 54.24% of US stocks.
  • The strongest trend for XLRN is in Growth, which has been heading down over the past 52 weeks.
  • XLRN's current lowest rank is in the Momentum metric (where it is better than 8.93% of US stocks).

XLRN Stock Summary

  • The ratio of debt to operating expenses for Acceleron Pharma Inc is higher than it is for about just 10.43% of US stocks.
  • XLRN's price/sales ratio is 96.94; that's higher than the P/S ratio of 96.63% of US stocks.
  • XLRN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 7.36% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Acceleron Pharma Inc are RARE, BCYC, FOLD, GNTX, and PXLW.
  • XLRN's SEC filings can be seen here. And to visit Acceleron Pharma Inc's official web site, go to www.acceleronpharma.com.

XLRN Valuation Summary

  • XLRN's price/sales ratio is 80.6; this is 610.13% higher than that of the median Healthcare stock.
  • Over the past 97 months, XLRN's EV/EBIT ratio has gone down 51.2.
  • Over the past 97 months, XLRN's price/sales ratio has gone up 69.9.

Below are key valuation metrics over time for XLRN.

Stock Date P/S P/B P/E EV/EBIT
XLRN 2021-08-31 80.6 10.7 -36.5 -35.1
XLRN 2021-08-30 80.0 10.6 -36.2 -34.7
XLRN 2021-08-27 78.0 10.3 -35.3 -33.9
XLRN 2021-08-26 76.6 10.1 -34.6 -33.2
XLRN 2021-08-25 76.5 10.1 -34.6 -33.2
XLRN 2021-08-24 75.4 10.0 -34.1 -32.7

XLRN Growth Metrics

  • Its 4 year net cashflow from operations growth rate is now at -287.28%.
  • The year over year net cashflow from operations growth rate now stands at -33.03%.
  • Its 3 year net income to common stockholders growth rate is now at -195.3%.
XLRN's revenue has moved up $87,246,000 over the prior 33 months.

The table below shows XLRN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 101.126 -193.265 -223.632
2021-03-31 112.938 -151.706 -178.562
2020-12-31 92.523 -130.327 -166.03
2020-09-30 105.995 -108.448 -132.21
2020-06-30 87.642 -142.697 -138.334
2020-03-31 75.556 -114.041 -137.745

XLRN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XLRN has a Quality Grade of D, ranking ahead of 17.88% of graded US stocks.
  • XLRN's asset turnover comes in at 0.131 -- ranking 236th of 682 Pharmaceutical Products stocks.
  • BMY, CPRX, and REPH are the stocks whose asset turnover ratios are most correlated with XLRN.

The table below shows XLRN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.131 1 -0.683
2021-06-30 0.113 1 -0.698
2021-03-31 0.140 1 -0.712
2020-12-31 0.131 1 -0.837
2020-09-30 0.177 1 -0.639
2020-06-30 0.178 1 -0.571

XLRN Stock Price Chart Interactive Chart >

Price chart for XLRN

XLRN Price/Volume Stats

Current price $178.75 52-week high $189.99
Prev. close $179.68 52-week low $108.82
Day low $177.06 Volume 7,884,200
Day high $179.85 Avg. volume 572,759
50-day MA $168.57 Dividend yield N/A
200-day MA $137.67 Market Cap 10.93B

Acceleron Pharma Inc. (XLRN) Company Bio


Acceleron Pharma XLRN is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company was founded in 2003 and is based in Cambridge, Massachusetts.


XLRN Latest News Stream


Event/Time News Detail
Loading, please wait...

XLRN Latest Social Stream


Loading social stream, please wait...

View Full XLRN Social Stream

Latest XLRN News From Around the Web

Below are the latest news stories about Acceleron Pharma Inc that investors may wish to consider to help them evaluate XLRN as an investment opportunity.

Sphinx Trading LP Takes $120,000 Position in Acceleron Pharma Inc. (NASDAQ:XLRN)

Sphinx Trading LP bought a new stake in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 700 shares of the biopharmaceutical companys stock, valued at approximately $120,000. Several other large investors also recently added to or reduced []

Dakota Financial News | November 22, 2021

Merck Closes Biggest Biotech Deal of the Year

The purchase of Acceleron Pharma gives Merck one more arrow in its quiver as it prepares for the patent on its blockbuster cancer therapeutic Keytruda to expire.

Yahoo | November 22, 2021

Merck completes tender offer for $11B Acceleron Pharma acquisition

No summary available.

Seeking Alpha | November 20, 2021

Acceleron Pharma (NASDAQ:XLRN) vs. Brickell Biotech (NASDAQ:BBI) Head to Head Comparison

Acceleron Pharma (NASDAQ:XLRN) and Brickell Biotech (NASDAQ:BBI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Insider and Institutional Ownership 90.4% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 14.2% []

Dakota Financial News | November 19, 2021

Fulton Bank N.A. Buys Shares of 1,507 Acceleron Pharma Inc. (NASDAQ:XLRN)

Fulton Bank N.A. bought a new stake in Acceleron Pharma Inc. (NASDAQ:XLRN) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,507 shares of the biopharmaceutical companys stock, valued at approximately $260,000. Other institutional investors and hedge funds have also recently made changes to []

Dakota Financial News | November 18, 2021

Read More 'XLRN' Stories Here

XLRN Price Returns

1-mo N/A
3-mo 2.88%
6-mo 45.55%
1-year 34.94%
3-year 336.08%
5-year 632.58%
YTD N/A
2021 0.00%
2020 141.31%
2019 21.75%
2018 2.62%
2017 66.30%

Continue Researching XLRN

Here are a few links from around the web to help you further your research on Acceleron Pharma Inc's stock as an investment opportunity:

Acceleron Pharma Inc (XLRN) Stock Price | Nasdaq
Acceleron Pharma Inc (XLRN) Stock Quote, History and News - Yahoo Finance
Acceleron Pharma Inc (XLRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.6542 seconds.